Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of$ 0.13 per share. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.38%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.23 per share when it actually produced a loss of $0.18, delivering a surprise of 21.74%.Nektar, which belong ...